Y Intercept Hong Kong Ltd Acquires Shares of 21,728 Maze Therapeutics, Inc. $MAZE

Y Intercept Hong Kong Ltd acquired a new position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 21,728 shares of the company’s stock, valued at approximately $649,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in MAZE. Royal Bank of Canada lifted its holdings in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after purchasing an additional 363 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Maze Therapeutics during the 4th quarter worth approximately $39,000. Ameritas Investment Partners Inc. increased its position in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after buying an additional 738 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in Maze Therapeutics during the fourth quarter worth approximately $43,000. Finally, Russell Investments Group Ltd. lifted its stake in Maze Therapeutics by 947.8% in the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after buying an additional 1,725 shares during the last quarter.

Maze Therapeutics Price Performance

Maze Therapeutics stock opened at $29.18 on Tuesday. Maze Therapeutics, Inc. has a 12 month low of $12.81 and a 12 month high of $53.65. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. The business has a 50 day simple moving average of $26.68 and a 200-day simple moving average of $35.22. The stock has a market capitalization of $1.62 billion, a PE ratio of -11.53 and a beta of 2.14.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The company had revenue of $20.00 million for the quarter. Equities analysts predict that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on MAZE shares. Wedbush raised their target price on shares of Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a research report on Monday, March 16th. JPMorgan Chase & Co. upped their price target on shares of Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, March 31st. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Finally, Truist Financial reduced their target price on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, April 14th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $66.00.

Insider Transactions at Maze Therapeutics

In other news, CEO Jason V. Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total value of $1,034,339.98. Following the sale, the chief executive officer owned 23,337 shares of the company’s stock, valued at $699,643.26. The trade was a 59.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 14,609 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $29.90, for a total transaction of $436,809.10. Following the transaction, the chief marketing officer directly owned 14,609 shares of the company’s stock, valued at $436,809.10. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 141,470 shares of company stock worth $3,887,939. Company insiders own 5.30% of the company’s stock.

Maze Therapeutics Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.